Literature DB >> 15810068

Loss of heterozygosity in multistage carcinogenesis of esophageal carcinoma at high-incidence area in Henan Province, China.

Ji-Ye An1, Zong-Min Fan, Shan-Shan Gao, Ze-Hao Zhuang, Yan-Ru Qin, Ji-Lin Li, Xin He, George-Sai-Wah Tsao, Li-Dong Wang.   

Abstract

AIM: Microsatellites are the repeated DNA sequences scattered widely within the genomes and closely linked with many important genes. This study was designed to characterize the changes of microsatellite DNA loss of heterozygosity (LOH) in esophageal carcinogenesis.
METHODS: Allelic deletions in 32 cases of matched precancerous, cancerous and normal tissues were examined by syringe microdissection under an anatomic microscope and microsatellite polymorphism analysis using 15 polymorphic markers on chromosomes 3p, 5q, 6p, 9p, 13q, 17p, 17q and 18q.
RESULTS: Microsatellite DNA LOH was observed in precancerous and cancerous tissues, except D9S1752. The rate of LOH increased remarkably with the lesions progressed from basal cell hyperplasia (BCH) to squamous cell carcinoma (SCC) (P<0.05). Three markers, D9S171, D13S260 and TP53, showed the highest incidence of LOH (>60%). LOH loci were different in precancerous and cancerous tissues. LOH in D3S1234 and TP53 was the common event in different lesions from the same patients.
CONCLUSION: Microsatellite DNA LOH occurs in early stage of human esophageal carcinogenesis, even in BCH. With the lesion progressed, gene instability increases, the accumulation of this change may be one of the important mechanisms driving precancerous lesions to cancer.

Entities:  

Mesh:

Year:  2005        PMID: 15810068      PMCID: PMC4305771          DOI: 10.3748/wjg.v11.i14.2055

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  25 in total

1.  Genetic progression and heterogeneity associated with the development of esophageal squamous cell carcinoma.

Authors:  M J Roth; N Hu; M R Emmert-Buck; Q H Wang; S M Dawsey; G Li; W J Guo; Y Z Zhang; P R Taylor
Journal:  Cancer Res       Date:  2001-05-15       Impact factor: 12.701

2.  Knudson's hypothesis and the TP53 revolution.

Authors:  Suzanne J Baker; Kenneth W Kinzler; Bert Vogelstein
Journal:  Genes Chromosomes Cancer       Date:  2003-12       Impact factor: 5.006

3.  Lymph node metastasis is associated with allelic loss on chromosome 13q12-13 in esophageal squamous cell carcinoma.

Authors:  H Harada; H Tanaka; Y Shimada; M Shinoda; M Imamura; K Ishizaki
Journal:  Cancer Res       Date:  1999-08-01       Impact factor: 12.701

Review 4.  Loss of heterozygosity as a predictor to map tumor suppressor genes in cancer: molecular basis of its occurrence.

Authors:  Sam Thiagalingam; Rebecca L Foy; Kuang-hung Cheng; Hyunjoo J Lee; Arunthathi Thiagalingam; Jose F Ponte
Journal:  Curr Opin Oncol       Date:  2002-01       Impact factor: 3.645

Review 5.  Genetic aberrations in oral or head and neck squamous cell carcinoma 2: chromosomal aberrations.

Authors:  C Scully; J K Field; H Tanzawa
Journal:  Oral Oncol       Date:  2000-07       Impact factor: 5.337

6.  Frequent hypermethylation of promoter region of RASSF1A in tumor tissues and voided urine of urinary bladder cancer patients.

Authors:  Michael W Y Chan; Lung W Chan; Nelson L S Tang; Kwok Wai Lo; Joanna H M Tong; Anthony W H Chan; Ho Y Cheung; Wai S Wong; Peter S F Chan; Fernand M M Lai; Ka Fai To
Journal:  Int J Cancer       Date:  2003-05-01       Impact factor: 7.396

7.  Allele loss and promoter hypermethylation of VHL, RAR-beta, RASSF1A, and FHIT tumor suppressor genes on chromosome 3p in esophageal squamous cell carcinoma.

Authors:  Tamotsu Kuroki; Francesco Trapasso; Sai Yendamuri; Ayumi Matsuyama; Hansjuerg Alder; Masaki Mori; Carlo M Croce
Journal:  Cancer Res       Date:  2003-07-01       Impact factor: 12.701

Review 8.  Structural insights into BRCA2 function.

Authors:  Yousif Shamoo
Journal:  Curr Opin Struct Biol       Date:  2003-04       Impact factor: 6.809

9.  p53 protein accumulation and gene mutations in multifocal esophageal precancerous lesions from symptom free subjects in a high incidence area for esophageal carcinoma in Henan, China.

Authors:  L D Wang; Q Zhou; J Y Hong; S L Qiu; C S Yang
Journal:  Cancer       Date:  1996-04-01       Impact factor: 6.860

10.  RASSF1A is a target tumor suppressor from 3p21.3 in nasopharyngeal carcinoma.

Authors:  Lillian Shuk-Nga Chow; Kwok-Wai Lo; Joseph Kwong; Ka-Fai To; Kam-Sze Tsang; Ching-Wan Lam; Reinhard Dammann; Dolly P Huang
Journal:  Int J Cancer       Date:  2004-05-10       Impact factor: 7.396

View more
  6 in total

1.  Esophageal squamous cell carcinoma - precursor lesions and early diagnosis.

Authors:  Antonio Barros Lopes; Renato Borges Fagundes
Journal:  World J Gastrointest Endosc       Date:  2012-01-16

2.  Aberrant methylation of different DNA repair genes demonstrates distinct prognostic value for esophageal cancer.

Authors:  Zhi-Qiang Ling; Pei Li; Ming-Hua Ge; Fu-Jun Hu; Xian-Hua Fang; Zi-Min Dong; Wei-Min Mao
Journal:  Dig Dis Sci       Date:  2011-06-15       Impact factor: 3.199

3.  XAF1 is frequently methylated in human esophageal cancer.

Authors:  Xiang-Yu Chen; Qiao-Yu He; Ming-Zhou Guo
Journal:  World J Gastroenterol       Date:  2012-06-14       Impact factor: 5.742

Review 4.  Chemoprevention of esophageal squamous cell carcinoma.

Authors:  Gary D Stoner; Li-Shu Wang; Tong Chen
Journal:  Toxicol Appl Pharmacol       Date:  2007-03-15       Impact factor: 4.219

5.  Loss of heterozygosity and microsatellite instability as predictive markers among Iranian esophageal cancer patients.

Authors:  Mohammad Mahdi Forghanifard; Elham Emami Vahid; Ezzat Dadkhah; Mehran Gholamin; Samaneh Broumand Noghabi; Martha Ghahraman; Mehdi Farzadnia; Mohammad Reza Abbaszadegan
Journal:  Iran J Basic Med Sci       Date:  2016-07       Impact factor: 2.699

Review 6.  Genetic and molecular bases of esophageal Cancer among Iranians: an update.

Authors:  Mohammad Reza Abbaszadegan; Vahideh Keyvani; Meysam Moghbeli
Journal:  Diagn Pathol       Date:  2019-08-31       Impact factor: 2.644

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.